Pep-Rani en es it fr

Pep-Rani Brand names, Pep-Rani Analogs

Pep-Rani Brand Names Mixture

  • Tritec (ranitidine bismuth citrate salt)

Pep-Rani Chemical_Formula


Pep-Rani RX_link

Pep-Rani fda sheet

Pep-Rani FDA

Pep-Rani msds (material safety sheet)

Pep-Rani MSDS

Pep-Rani Synthesis Reference

B. J. Price et al., U.S. Pat. 4,128,658 (1978)

Pep-Rani Molecular Weight

314.405 g/mol

Pep-Rani Melting Point

69-70 oC

Pep-Rani H2O Solubility

24.7 mg/mL

Pep-Rani State


Pep-Rani LogP


Pep-Rani Dosage Forms

Capsule; Liquid; Solution; Tablet; Syrup

Pep-Rani Indication

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Pep-Rani Pharmacology

Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

Pep-Rani Absorption

Approximately 50% bioavailability orally.

Pep-Rani side effects and Toxicity

LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

Pep-Rani Patient Information


Phenylketonurics: ZANTAC 25 EFFERdose Tablets contain phenylalanine 2.81 mg per 25 mg of ranitidine. ZANTAC 150 EFFERdose Tablets
contain phenylalanine 16.84 mg per 150 mg of ranitidine. ZANTAC EFFERdose Tablets should not be chewed, swallowed whole, or dissolved
on the tongue.

Pep-Rani Organisms Affected

Humans and other mammals